Investigating GDF-15's role as a biomarker for cardiovascular disease, suggesting implications for management and treatment.
GDF-15 captures distinct aspects of CV disease development, progression, and prognosis, which are not represented by clinical risk predictors and other biomarkers. The usefulness of GDF-15 to guide management decisions and discover new treatment targets should be further explored.
No takes yet. Share an insight, caveat, or question.
Wollert et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: